Destiny Buch's questions to OPKO Health Inc (OPK) leadership • Q3 2024
Question
Destiny Buch, on behalf of Jeff Cohen, asked for clarification on the MDX-2201 EBV vaccine program, specifically regarding who makes the decision to advance it into the clinic. She also questioned whether BioReference's path to profitability requires additional investment or if the current restructuring and cost-cutting measures are sufficient.
Answer
Executive Elias Zerhouni clarified that Merck, as the program sponsor, holds the final decision-making authority for advancing MDX-2201 and that there are no outstanding obstacles. Regarding BioReference, executive Adam Logal stated that the nonrecurring restructuring costs are the primary driver for profitability and significant new investments are not required. Zerhouni added that rightsizing the infrastructure and focusing on the NY/NJ market will drive efficiency.